LOS ANGELES, June 7, 2018 /PRNewswire/ -- CytRx
Corporation (Nasdaq: CYTR), a biopharmaceutical research and
development company specializing in oncology, today highlighted
clinical data from partner NantCell's poster presentation on
June 2, 2018 at the American Society
of Clinical Oncology (ASCO) 2018 Annual Meeting, in Chicago. The data clearly demonstrates the
lack of cardiac toxicity associated with treatment with
aldoxorubicin. These results were obtained from two clinical trials
of aldoxorubicin, a rationally-engineered cytotoxic which employs a
linker bound to albumin to deliver doxorubicin directly into the
tumor.
Fifty-two patients from a Phase 1/2 study of aldoxorubicin and
ifosfamide/mesna, and a Phase 3 study using aldoxorubicin alone
were evaluated. Data from a global Phase 2
(INNO-206-P2-STS-01) and Phase 3 (P3-STS-01) clinical study of
doxorubicin versus aldoxorubicin was also reviewed. Cardiac
function was evaluated by echocardiogram at regular intervals. The
median cumulative dose of aldoxorubicin was 2,800 mg/m2
(range 1,500-9,000 mg/m2), equivalent to 2,080
mg/m2 (range 1,115-6,687 mg/m2) of
doxorubicin. Results from the study showed that no patient
developed any sign or symptom of clinical congestive heart failure.
Ventricular ejection fractions ranged from 45-74% baseline,
and 50-77% at the end of treatment, with the median being 60% both
at the beginning and at the end of treatment.
"Doxorubicin's use in treating sarcomas has always been limited
due to its known cardiotoxicity profile," said Sant Chawla M.D., F.R.A.C.P., Director of the
Sarcoma Oncology Center in Santa
Monica and Principal Investigator for both studies. "The
data presented this year at ASCO show that aldoxorubicin can be
administered safely alone, or with continuous infusion of
ifosfamide/mesna, without causing cardiotoxicity. Importantly, no
clinically significant cardiac problems were observed with median
cumulative dose of aldoxorubicin of 2,800 mg/m2, which
is equivalent to 2,080 mg/m2 of doxorubicin. These
results continue to build upon the growing body of safety data for
aldoxorubicin."
CytRx out-licensed global development, manufacturing, and
commercialization rights for aldoxorubicin to NantCell, Inc., a
private subsidiary of NantWorks, LLC, in July 2017.
About ASCO
The American Society of Clinical Oncology Annual Meeting is
one of the largest and most influential conferences in the field.
It is an international gathering that brings together more than
40,000 oncology professionals, thought leaders, patient advocates
and the general public to present cutting-edge treatment
modalities, discuss new therapies, and debate ongoing
controversies. The 2018 meeting will take place
in Chicago, June 1 through June 5. ASCO provides
conference attendees with a variety of perspectives on treatment
through debates, tumor boards, presentations of abstracts, and Meet
the Professor sessions. New in 2018, the conference will
feature ASCO Voices, a thought-provoking one-hour
session devoted to the presentation of 7-minute long talks that
convey the speaker's ideas and passion, without incorporating
slides, data or figures of any kind.
About CytRx Corporation
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical company
with expertise in discovering and developing new therapeutics to
treat patients with cancer. CytRx's wholly owned subsidiary,
Centurion BioPharma Corporation, is focused on advancing a
portfolio of novel, anti-cancer drug candidates that employ its
LADR™ (Linker Activated Drug Release) technology, a discovery
engine designed to leverage the Company's expertise in albumin
biology and linker technology for the development of a new class of
potential breakthrough anti-cancer therapies. A critical element of
the LADR™ platform is its ability to bind anti-cancer molecules to
albumin, the most ubiquitous protein in human blood plasma, and
then to release the highly potent cytotoxic payload at the tumor
site. This technology allows for the delivery of higher doses of
drug directly to the tumor, while avoiding much of the off-target
toxicity observed with the parent molecules. CytRx's most
advanced drug conjugate, aldoxorubicin, is an improved version of
the widely used anti-cancer drug doxorubicin and has been
out-licensed to NantCell, Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; Centurion BioPharma Corporation's ability to
develop new ultra-high potency drug candidates based on its LADR™
technology platform; our ability to attract potential licensees;
and other risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
cytrx@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-nantcell-incs-aldoxorubicin-clinical-data-presented-at-the-american-society-of-clinical-oncology-2018-annual-meeting-300661334.html
SOURCE CytRx Corporation